Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis

Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors

(2015) Melissa A. Lerman et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus

(2015) Rosa Bou et al.   RHEUMATOLOGY INTERNATIONAL

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

(2015) Ivan Foeldvari et al.   ARTHRITIS CARE & RESEARCH

Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results

(2014) Deshka Doycheva et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Development of Macular Edema and Impact on Visual Acuity in Uveitis Associated with Juvenile Idiopathic Arthritis

(2014) Joke de Boer et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting

(2014) Maarit Tarkiainen et al.   RHEUMATOLOGY

Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

(2014) Heinrike Schmeling et al.   Arthritis & Rheumatology

Adalimumab for juvenile idiopathic arthritis-associated uveitis

(2013) Adriano Magli et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis

(2013) Carmen García-De-Vicuña et al.   MEDIATORS OF INFLAMMATION

Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk Factors

(2013) Arnd Heiligenhaus et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

(2013) Gabriele Simonini et al.   Pediatric Rheumatology

Current Evidence of Anti-Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach of Individual Drugs

(2013) Gabriele Simonini et al.   ARTHRITIS CARE & RESEARCH

Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry

(2012) M. E. ZANNIN et al.   JOURNAL OF RHEUMATOLOGY

Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study

(2012) Anthony C. Gregory et al.   OPHTHALMOLOGY

Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: A consensus effort from the multinational interdisciplinary working group for uveitis in childhood

(2012) Arnd Heiligenhaus et al.   ARTHRITIS CARE & RESEARCH

Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis

(2011) A. Heiligenhaus et al.   RHEUMATOLOGY INTERNATIONAL

Prevention of flare recurrences in childhood-refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab

(2010) Gabriele Simonini et al.   ARTHRITIS CARE & RESEARCH